Nipah Virus International Conference

Scientific Programme

Nipah Virus International Conference (NVIC)

Conference objective: to stimulate dialogue among Nipah virus (NiV) experts and other stakeholders in order to accelerate the development of NiV diagnostics, vaccines and other medical countermeasures against NiV.

Day 1 Monday (9 Dec 2019)

08.00 - 16.00	Arrival and registration
09.00 - 09.30	OPENING CEREMONY AND WELCOME ADDRESS WELCOME BY CONFERENCE CHAIRS Prof Linfa Wang, Duke-NUS Medical School Dr Raúl Gómez Román, CEPI WELCOME BY CONFERENCE CHAIRS Prof Linfa Wang, Duke-NUS Medical School Dr Raúl Gómez Román, CEPI MESSAGE FROM MINISTRY OF HEALTH, SINGAPORE SMS Dr Lam Pin Min Senior Minister of State for Health and Transport MESSAGE FROM THE MINISTRY OF HEALTH, MALAYSIA Datuk Dr. Christopher Lee Kwok Choong Deputy Director General of Health (Research & Technical Support) MESSAGE FROM THE WHO Dr Michael Ryan Executive Director, WHO Health Emergencies Programme MESSAGE FROM NIAID Dr Cristina Cassetti Deputy Director, Division of Microbiology and Infectious Diseases, NIAID, NIH WELCOME ADDRESS Prof Thomas Coffman Dean, Duke-NUS Medical School INAUGURAL ADDRESS Dr Richard Hatchett CEO, CEPI
09.30 - 10.00	SESSION 1 - HISTORIC REVIEW OF NIPAH OUTBREAKS Chair: Dr Marie-Pierre Preziosi, WHO OVERVIEW OF OUTBREAKS – Prof John Mackenzie, Curtin University Australia - Dr Hume Field, EcoHealth Alliance and University of Queensland Malaysia – Dr Chua Kaw Bing, Temasek Lifesciences Laboratory Singapore – Prof Leo Yee Sin, National Centre for Infectious Diseases Bangladesh - Prof Mahmudur Rahman, Programme for Emerging Infections, icddr,b India - Dr Nivedita Gupta, Division of Epidemiology Communicable Diseases, ICMR Philippines – Dr Fidel Malbas Jr, Research Institute for Tropical Medicine
10.10 - 10.30	Group Photo
10.30 - 11.00	Coffee, Exhibition and Poster Viewing
11.00 - 11.30	SESSION 2 - WHO NIPAH R&D ROAD MAP Chair: Dr Christina Spiropoulou, CDC Prof Stephen Luby, Stanford University Dr Claudia Nannei, WHO
11.30 - 13.00	SESSION 3 - PROGRESS AND CHALLENGES IN SURVEILLANCE Chair:Dr Peter Daszak,EcoHealth Alliance NIPAH SURVEILLANCE IN BANGLADESH Prof Mahmudur Rahman, Programme for Emerging Infections, icddr,b NIPAH VIRUS DYNAMICS IN BATS AND IMPLICATIONS FOR ZOONOTIC SPILLOVER TO HUMANS Dr Jonathan Epstein, EcoHealth Alliance SURVEY OF PTEROPUS BATS DURING NIPAH OUTBREAK IN INDIA REVEALED ITS ASSOCIATION Dr Pragya Yadav, National Institute of Virology, ICMR LONG-TERM ONE HEALTH SURVEILLANCE OF NIPAH VIRUS IN THAILAND FOREWARNS RISK OF OUTBREAK Dr Supaporn Wacharapluesadee, Chulalongkorn University HENIPAVIRUS BIOSURVEILLANCE IN SOUTH AFRICAN BATS – A RESEARCH OVERVIEW Prof Wanda Markotter, University of Pretoria
13.00 - 14.00	LUNCH PHOTO/VIDEO EXHIBITION FROM MALAYSIA Dr Eva Tiong & Prof Chua Kaw Bing
14.00 - 15.30	SESSION 4 - PROGRESS AND CHALLENGES IN DIAGNOSTICS Chair: Dr Joel Montgomery, CDC OVERVIEW OF NIPAH DIAGNOSTICS Dr Jilian Sacks, FIND THE WHO NIPAH DIAGNOSTICS TARGET PRODUCT PROFILE (TPP) Dr Laura Mazzola, WHO ROLE OF EARLY DIAGNOSIS DURING NIPAH VIRUS OUTBREAK IN INDIA Dr Pragya Yadav, National Institute of Virology, ICMR NIPAH VIRUS DIAGNOSTICS AT CDC - CURRENT STRATEGIES Dr John Klena, CDC HENDRA DIVA ASSAY FOR THE DETECTION OF ANTIBODIES IN VACCINATED HORSES Dr Kim Halpin, CSIRO, AAHL SEROLOGICAL ASSAYS FOR HENIPAVIRUS DIAGNOSTICS Prof Anne Balkema-Buschmann, Friedrich Loeffler Institut ESTABLISHMENT OF AN IMMUNOFLUORESCENCE ASSAY TO DETECT IgM ANTIBODIES TO NIPAH VIRUS USING HELA CELLS EXPRESSING RECOMBINANT NUCLEOPROTEIN Dr Yoshihiro Kaku, National Institute of Infectious Diseases
15.30 - 16.00	Coffee, Exhibition and Poster Viewing
16.00 - 17.30	SESSION 5 - PATHOGENESIS AND ANIMAL MODELS Chair: Dr Amy Shurtleff, CEPI DEVELOPMENT OF A NONHUMAN PRIMATE MODEL FOR NIPAH VIRUS INFECTION THAT ACCURATELY REFLECTS HUMAN DISEASE Dr Mike Holbrook, NIAID, NIH ADVANCES IN NON-HUMAN PRIMATE MODELS OF HENIPAVIRUS DISEASE: REFINEMENT OF ROUTES AND THE IMPORTANCE OF SPECIES SELECTION Dr Robert Cross, UTMB ORONASAL CHALLENGE OF FERRETS WITH HENIPAVIRUSES Dr Glenn Marsh, CSIRO, AAHL NIPAH VIRUS PATHOGENESIS IN EXPERIMENTALLY INFECTED SWINE Dr Brad Pickering, Canadian Food Inspection Agency
17.30 - 19.00	Poster Viewing and Happy Hour
19.00 - 21.00	Conference Dinner

Day 2 Tuesday (10 Dec 2019)

08.00 - 13.00	REGISTRATION
08.30 - 10.00	SESSION 6 - TRANSMISSION/CASE MANAGEMENT Chair: Dr Pierre Formenty, WHO PERSON-TO-PERSON TRANSMISSION OF NIPAH VIRUS Dr Emily Gurley, Johns Hopkins Bloomberg School of Public Health PATIENT MANAGEMENT & INFECTION CONTROL PRACTICES Dr Chandni Sajeevan, Government Medical College A CASE-CONTROL STUDY OF HENIPAVIRUS OUTBREAK, PHILIPPINES, 2014 Dr Paola Katrina Ching, Dr Jose N. Rodriguez Memorial Hospital LESSONS LEARNED FROM PATHOLOGY AND DISEASE COURSE: MALAYSIA Prof Kum Thong Wong, University of Malaya
10.00 - 10.30	Coffee, Exhibition and Poster Viewing
10.30 - 12.00	SESSION 7 - EPIDEMIOLOGICAL NEEDS FOR CLINICAL TRIALS Chair: Dr Jakob Cramer, CEPI APPROACHES TO DEMONSTRATE THE EFFECTIVENESS OF NIPAH VACCINES Dr Ana Maria Henao Restrepo, WHO R&D Blueprint RESOLVING EPIDEMIOLOGICAL UNCERTAINTIES TO INFORM DEVELOPMENT OF NIPAH COUNTERMEASURES Prof Stephen Luby, Stanford University PRACTICAL ISSUES IN ADVANCING HUMAN TESTING OF NIPAH VACCINES IN BANGLADESH Dr K Zaman, icddr,b EPIDEMIOLOGIC PREPAREDNESS FOR NIPAH VACCINE/THERAPEUTIC TRIALS Dr Tarun Bhatnagar, National Institute of Epidemiology, ICMR CURRENT EPIDEMIOLOGICAL STATUS OF NIPAH VIRUS ENCEPHALITIS IN MALAYSIA IN THE CONTEXT OF VACCINE/THERAPEUTIC TRIALS Prof Tan Chong Tin, University of Malaya
12.00 - 13.00	LUNCH THIS WEEK IN VIROLOGY (TWiV) Prof Vincent Racaniello
13.00 - 14.30	SESSION 8 - PROGRESS AND CHALLENGES IN VACCINE DEVELOPMENT Chair: Dr Melanie Saville,CEPI NIPAH VACCINES: OVERVIEW Dr Eun-Chung Park, NIAID, NIH A SUBUNIT VACCINE (HeV-sG-V) TO PROTECT AGAINST NIPAH AND HENDRA DISEASE Dr Rong Xu, Profectus BioSciences Inc. ChAdOx1 NIPAH VACCINE Prof Sarah Gilbert, Jenner Institute, University of Oxford DEVELOPMENT OF MEASLES VIRUS-VECTOR VACCINE FOR NIPAH VIRUS INFECTION Prof Chieko Kai, University of Tokyo DEVELOPMENT OF A VESICULAR STOMATITIS VIRUS-BASED VACCINE TO PREVENT NIPAH VIRUS DISEASE Dr Gray Heppner, Crozet BioPharma LLC F VS G NIPAH VACCINES: STABILIZING THE PRE-FUSION CONFORMATION OF F FOR A FAIR COMPARISON Dr Keith Chappell, University of Queensland DEVELOPING A ‘ONE HEALTH’ NIPAH VIRUS VACCINE TO PROTECT ANIMAL AND PUBLIC HEALTH Dr Simon Graham, The Pirbright Institute
14.30 - 16.00	SESSION 9 - PROGRESS AND CHALLENGES IN THERAPEUTICS DEVELOPMENT Chair: Prof Benhur Lee,Mt. Sinai School of Medicine OPUTATIVE NIPAH THERAPEUTICS: PATHOPHYSIOLOGIC, TARGET PROFILE, AND TRIAL DESIGN CONSIDERATIONS Dr Elizabeth Higgs, NIAID, NIH MONOCLONAL ANTIBODY COUNTERMEASURES FOR PATHOGENIC HENIPAVIRUSES Prof Christopher Broder, Uniformed Services University THERAPEUTIC REMDESIVIR TREATMENT PROTECTS AFRICAN GREEN MONKEYS FROM LETHAL NIPAH VIRUS, BANGLADESH CHALLENGE Dr Emmie de Wit, NIAID, NIH INHIBITION OF NIPAH VIRUS INFECTION BY TARGETING VIRAL CELL ATTACHMENT AND ENTRY Dr Branka Horvat, INSERM CHARACTERIZATION OF NOVEL INHIBITORS OF NIPAH VIRUS Dr Michael Lo, US, CDC
16.00 - 16.15	Coffee, Exhibition and Poster Viewing
16.15 - 17.15	SESSION 10 - PANEL DISCUSSION: COLLABORATION & SYNERGY Chairs: Prof Linfa Wang & Dr Raúl Gómez Román 1. EXCHANGE OF MATERIALS AND SOPS, BIOBANKING 2. INTER-NATIONS COLLABORATION SINO-FRENCH NiV TASKFORCE Dr Zhengli Shi, Wuhan Institute of Virology, Chinese Academy of Sciences UPDATE FROM SEARO MEETING AND THE INTERNATIONAL RESEARCH COLLABORATION PLATFORM IN INDIA/BANGLADESH (REQUIREMENTS FOR THERAPEUTICS TRIALS) Dr Nivedita Gupta, Division of Epidemiology & Communicable Diseases, ICMR COMMENTS FROM REPRESENTATIVES FROM WHO REGIONAL OFFICES (SEARO & WIPRO) 3. CHALLENGES IN VACCINE SAFETY MONITORING NEED TO MAXIMIZE SAFETY MONITORING ACROSS PROGRAMME Dr Robert Chen, Brighton Collaboration 4. GENERAL DISCUSSION
17.15 - 17.30	Prize Presentation and Closing Ceremony

Day 3 Wednesday (11 Dec 2019) Optional

9:00 - 12:00	Tour of National Center for Infectious Diseases (NCID)

(Note: a total of 30 participants can be accommodated on a first come first serve basis)